Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645091 | 1.00 | SIRT6 (0.58) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL17631074 | 1.00 | SIRT6 (0.58) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL22471521 | 0.80 | SIRT6 (0.52) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL23524643 | 0.80 | MAPT (0.55) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL23444413 | 0.80 | MAPT (0.55) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL23524639 | 0.80 | MAPT (0.55) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL6912775 | 0.80 | MAPT (0.55) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL12424153 | 0.80 | SIRT6 (0.47) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL25707166 | 0.79 | MAPT (0.56) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL8448356 | 0.78 | HRH3 (0.56) | SIRT6LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | SIRT6 1892/4885LMNA 3233/4885MAPT 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.